USANA cites weaker Core Nutritional, Rise Wellness sales in Q3 revenue decline
USNA•USANA Health Sciences’ third-quarter 2026 sales fell 4% to $206 million as declines in Core Nutritional and Rise Wellness outweighed Hiya growth. Net loss narrowed to $5.6 million, while adjusted EBITDA fell 13% to $12.1 million.
1. Third-quarter results
USANA Health Sciences reported third-quarter 2026 sales fell 4% to $206 million, as weaker Core Nutritional and Rise Wellness sales outweighed Hiya’s 2% growth to $32 million. Net loss attributable to USANA narrowed to $5.6 million from $6.5 million, while adjusted EBITDA fell 13% to $12.1 million.
2. Margins and correction
Core Nutritional’s operating margin rose to 4.1% from 1.2%, reflecting lower incentive costs, event expenses and employee compensation despite weaker sales. USANA corrected second-quarter adjusted EBITDA attributable to the company to $21.7 million from $27.8 million, removing noncontrolling interests’ share of an impairment add-back.
